Am I Eligible For Glp1 Medication Complete Bmi Health Criteria Guide

You have probably heard about GLP-1 medications and the results people are seeing. Maybe a friend lost 40 pounds, or you saw a story online that caught your attention. Now you want to know: do I actually qualify? Understanding GLP-1 eligibility requirements is the first step toward finding out if these medications are right for you.

Key Takeaways: - Understand what are the bmi requirements for glp-1 medications - Which Health Conditions Make You Eligible at a Lower BMI - Understand what are the age and medical history requirements - Learn how the formblends eligibility process works - Understand what if i have been denied before

The criteria are straightforward. Most people who struggle with their weight and have tried diet and exercise already meet the basic thresholds. This guide breaks down every qualification factor so you can walk into your consultation feeling confident and prepared.

What Are the BMI Requirements for GLP-1 Medications?

BMI, or body mass index, is the primary number providers look at when evaluating you for GLP-1 treatment. It is a simple calculation based on your height and weight. While it is not a perfect measure of health, it is the standard screening tool used by prescribers nationwide.

Here are the two main BMI thresholds for GLP-1 eligibility:

• BMI of 30 or higher: You may qualify based on BMI alone. A BMI of 30 is classified as obesity by the CDC. For reference, a person who is 5'6" and weighs 186 pounds has a BMI of 30.
• BMI of 27-29.9 with a qualifying health condition: If your BMI falls in the "overweight" range, you can still qualify if you have at least one weight-related comorbidity. We will cover those conditions in the next section.

Not sure where you stand? You can in about 10 seconds. It will give you an instant reading along with guidance on what the number means for GLP-1 qualification.

Keep in mind that BMI is a starting point, not the full picture. Your provider will also consider your overall health history, current medications, and weight loss goals before making a recommendation.

Waist Circumference: An Important Secondary Criterion

While BMI is the primary screening tool, many providers also consider waist circumference as a complementary measure of metabolic risk. Waist circumference captures visceral fat) the fat stored around your internal organs (which is more strongly associated with cardiometabolic disease than total body weight alone.

The clinical thresholds recognized by the National Heart, Lung, and Blood Institute are:

• Men: Waist circumference of 40 inches (102 cm) or greater indicates elevated metabolic risk
• Women: Waist circumference of 35 inches (88 cm) or greater indicates elevated metabolic risk

These thresholds are lower for certain populations. For individuals of South Asian, East Asian, or Southeast Asian descent, providers may use cutoffs of 35 inches (90 cm) for men and 31.5 inches (80 cm) for women, reflecting differences in body composition and metabolic risk at lower body weights.

Why does this matter for GLP-1 eligibility? If your BMI is in the 27-29.9 range and your waist circumference exceeds these thresholds, it strengthens the clinical case for treatment. Elevated waist circumference is often associated with insulin resistance, dyslipidemia, and inflammation) conditions that GLP-1 medications can directly address. Some providers may use waist circumference as supporting evidence when submitting prior authorization requests to insurance companies.

You can measure your waist circumference at home by wrapping a flexible tape measure around your bare abdomen at the level of your navel, standing upright and breathing normally. Make sure the tape is snug but not compressing the skin.

FDA-Approved Indications by Brand Name

Not all GLP-1 medications are approved for the same conditions. Understanding which brands are FDA-approved for which indications can help you deal with conversations with your provider and insurance company.

Brand Name	Active Ingredient	FDA-Approved For
Wegovy	Semaglutide 2.4 mg	Chronic weight management in adults with BMI 30+, or BMI 27+ with comorbidity; cardiovascular risk reduction
Ozempic	Semaglutide 0.5-2.0 mg	Type 2 diabetes (often used off-label for weight loss at lower doses)
Zepbound	Tirzepatide 5-15 mg	Chronic weight management in adults with BMI 30+, or BMI 27+ with comorbidity
Mounjaro	Tirzepatide 2.5-15 mg	Type 2 diabetes
Saxenda	Liraglutide 3.0 mg	Chronic weight management in adults and adolescents 12+
Victoza	Liraglutide 1.8 mg	Type 2 diabetes

The distinction between a weight management indication and a diabetes indication matters primarily for insurance coverage. If your provider prescribes a diabetes-indicated brand for weight loss, your insurer may deny the claim. Using the correct brand for the correct indication (or pursuing compounded formulations through FormBlends) can avoid this issue entirely.

Which Health Conditions Make You Eligible at a Lower BMI?

"Compounding pharmacies serve a critical role in healthcare, but patients need to understand the difference between a properly regulated 503B facility and an unregulated operation. Ask about PCAB accreditation and third-party testing.", Dr. Scott Brunner, PharmD, Alliance for Pharmacy Compounding

If your BMI is between 27 and 29.9, you may still qualify for GLP-1 treatment if you have one or more of the following comorbidities. These are conditions that are directly connected to excess weight and can improve with weight loss.

Common qualifying conditions include:

• Type 2 diabetes or prediabetes: Elevated blood sugar levels are one of the most common reasons providers prescribe GLP-1 medications. In fact, semaglutide and tirzepatide were originally developed for blood sugar management.
• High blood pressure (hypertension): Carrying extra weight puts strain on your cardiovascular system. Clinical trial data from the STEP and SURMOUNT programs demonstrate that GLP-1 medications can reduce blood pressure alongside weight loss.
• High cholesterol or triglycerides: Abnormal lipid levels often improve when body weight decreases. Your provider may check your latest lab work during your consultation.
• Obstructive sleep apnea: This condition, where breathing repeatedly stops during sleep, is strongly linked to excess weight. Losing even 10-15% of body weight can significantly reduce symptoms.
• PCOS (polycystic ovary syndrome): Many women with PCOS struggle with weight that is resistant to traditional approaches. GLP-1 medications may help with both weight and hormonal balance. Learn more about .
• Non-alcoholic fatty liver disease (NAFLD): Emerging research shows GLP-1 medications may benefit liver health in addition to supporting weight loss.

Your provider will verify these conditions during your consultation. Having documentation such as recent lab results or a diagnosis from your primary care doctor can speed up the process.

---

Free Download: GLP-1 Eligibility Self-Assessment Checklist Not sure if you check all the boxes? This printable checklist walks you through every eligibility factor so you can prepare for your consultation with confidence. Get yours free -- we will email it to you instantly. [Download Your Free Checklist]

---

Patient Perspective: "I was surprised I qualified (I didn't think of myself as 'obese enough' for medication. But my BMI was 32 with high blood pressure, and my provider explained that's exactly who these medications were designed for.") Nicole F., 42, FormBlends patient (name changed for privacy)

What Are the Age and Medical History Requirements?

Beyond BMI and comorbidities, providers look at a few other factors before prescribing GLP-1 medications.

Age requirements: GLP-1 medications are FDA-approved for adults aged 18 and older. Some formulations have been studied in adolescents aged 12-17, but prescribing in that age group requires additional evaluation. There is no upper age limit, although providers may adjust dosing and monitoring for patients over 65.

Contraindications to be aware of: Certain conditions may make GLP-1 medications unsafe for you. These include:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• History of pancreatitis
• Current pregnancy or plans to become pregnant in the near term
• Severe gastrointestinal conditions such as gastroparesis

Medication interactions: Your provider will review everything you currently take. GLP-1 medications can interact with insulin, sulfonylureas, and certain other drugs. This does not mean you cannot use them, but your provider may need to adjust your other medications.

Being honest about your full medical history is important. The consultation exists to protect your safety. If one GLP-1 medication is not right for you, your provider may recommend a different formulation or approach. You can to get personalized guidance based on your specific situation.

What to Expect at Your First Appointment

Walking into any medical appointment without knowing what to expect can feel stressful. Here is a step-by-step breakdown of what happens during a typical GLP-1 evaluation, whether in-person or via telehealth.

Before your appointment (what to prepare: Gather the following information ahead of time. Having this ready makes the consultation faster and helps your provider make the most informed recommendation.

• Your current height and weight (measured within the past week)
• A list of all current medications, including supplements and over-the-counter drugs
• Recent lab work if available (A1C, fasting glucose, lipid panel, liver function, kidney function)
• Your weight history) how long you have been overweight, past dieting attempts, and any previous weight loss medications
• Family medical history, especially thyroid conditions, pancreatitis, or endocrine disorders

During the appointment: Your provider will typically follow this sequence:

1. Medical history review. They will go through your health conditions, medications, allergies, and surgical history. Be thorough and honest (this protects your safety.
2. Weight and metabolic assessment. They will evaluate your BMI, discuss your weight trajectory, and review any relevant lab work. If you do not have recent labs, they may order bloodwork before prescribing.
3. Goal discussion. Your provider will ask what you hope to achieve and set realistic expectations. Clinical trial data shows average weight loss of 14.9% with semaglutide (STEP 1, Wilding et al., NEJM, 2021) and up to 22.5% with tirzepatide (SURMOUNT-1, Jastreboff et al., NEJM, 2022) at maximum doses over 68-72 weeks.
4. Medication selection. Based on your health profile, insurance situation, and goals, your provider will recommend a specific medication and starting dose.
5. Side effect counseling. You will learn what to expect during the first few weeks, how to manage common GI side effects, and when to contact your provider.
6. Injection training. If this is your first injectable medication, your provider or a nurse will walk you through the injection technique. Subcutaneous injections use a short, thin needle and are straightforward once you have done it a couple of times.

The entire appointment typically takes 15-30 minutes. Through FormBlends, telehealth consultations are often completed within 24-48 hours of starting the eligibility quiz.

How to deal with Insurance Pre-Authorization

If you are pursuing brand-name GLP-1 medications through insurance, understanding the pre-authorization process can save you significant time and frustration. Here is how it works.

Step 1: Verify your benefits. Before your provider submits anything, call your insurance company or check your plan documents to confirm whether anti-obesity medications are a covered benefit. Ask specifically about semaglutide (Wegovy) and tirzepatide (Zepbound) by name. Some plans cover one but not the other.

Step 2: Your provider submits a prior authorization request. This is a formal request that includes your clinical information) BMI, comorbidities, previous weight loss attempts, and relevant lab values. Your provider's office handles this paperwork.

Step 3: The insurer reviews the request. This typically takes 3-14 business days. The insurer will evaluate whether you meet their specific criteria, which may differ slightly from the FDA label. Common requirements include documented BMI at or above the threshold, at least one comorbidity, and documentation of failed attempts at lifestyle modification.

Step 4: Approval, denial, or request for more information. If approved, your prescription can be filled at a covered pharmacy. If denied, you have options:

• Peer-to-peer review: Your provider can request a phone call with the insurer's medical director to discuss your case directly. This overturns many initial denials.
• Formal appeal: You can file a written appeal with additional clinical documentation. Many insurers have a two-level internal appeal process.
• External review: If internal appeals fail, most states allow you to request an independent external review.

Step 5: Step therapy exceptions. If your insurer requires you to try a cheaper medication first (step therapy), your provider can request an exception if there is a clinical reason to bypass it (for example, a history of adverse reactions to the required medication, or documented failure on that medication.

The entire pre-authorization process can take anywhere from a few days to several weeks. For patients who want to start treatment quickly or who face repeated denials, compounded GLP-1 medications through FormBlends offer a simplified alternative that bypasses insurance entirely.

How the FormBlends Eligibility Process Works

Getting evaluated for GLP-1 treatment through FormBlends is designed to be simple and fast. Here is what the process looks like from start to finish.

Step 1: Take the online eligibility quiz. This takes about two minutes. You will answer questions about your height, weight, health history, and goals. The quiz gives you an immediate preliminary result. to see where you stand.

Step 2: Complete your telehealth consultation. A licensed provider reviews your information and meets with you virtually. They will ask follow-up questions, review any relevant lab work, and determine whether GLP-1 medication is appropriate for you.

Step 3: Receive your prescription. If approved, your provider writes a prescription for a personalized compounded medication prepared by a licensed US-based 503A pharmacy. The medication is tailored to your starting dose and titration schedule.

Step 4: Get your medication delivered. Your medication ships directly to your door, typically within 5-7 business days. The FormBlends app helps you .

The entire process from quiz to medication delivery usually takes about one to two weeks. Many patients complete their consultation within 24-48 hours of starting the quiz.

What If I Have Been Denied Before?

Getting denied for GLP-1 medication does not mean you are permanently ineligible. Denials happen for many reasons, and most of them can be addressed.

Common reasons for denial and what to do:

• BMI was too low at the time: Your weight may have changed since your last evaluation. A new assessment may yield different results.
• Insurance denied coverage: This is a coverage issue, not a medical one. Compounded GLP-1 medications through FormBlends offer an alternative path that does not require insurance approval. Check out our for current rates.
• Missing documentation: If your provider needed lab work or medical records that were not available, gathering those documents and trying again often resolves the issue.
• Different provider, different criteria: Eligibility standards can vary between practices. A telehealth platform that specializes in GLP-1 treatment may evaluate your case differently than a general practitioner.

The most important thing is not to give up. If you meet the BMI and health criteria outlined in this guide, you have a strong foundation for approval.

Frequently Asked Questions

What BMI do I need to qualify for GLP-1 medication?

You generally need a BMI of 30 or higher to qualify based on weight alone. If your BMI is between 27 and 29.9, you may still qualify if you have a weight-related health condition such as type 2 diabetes, high blood pressure, or sleep apnea. Use our to check your number.

Can I get GLP-1 medication if I am not diabetic?

Yes. While GLP-1 medications were originally developed for type 2 diabetes, several are now FDA-approved specifically for weight management in non-diabetic patients. Most GLP-1 prescriptions today are written for weight loss, not blood sugar control. Read our full guide on .

How fast can I get approved for GLP-1 treatment online?

Through FormBlends, many patients complete their consultation within 24-48 hours of taking the eligibility quiz. If approved, your prescription is sent to the pharmacy the same day. Medication delivery typically takes 5-7 business days after that.

Will my insurance cover GLP-1 medication?

Coverage varies widely by insurance plan and state. Many plans require prior authorization, and some exclude weight loss medications entirely. FormBlends offers compounded GLP-1 medications at transparent cash-pay prices, which can be more affordable than brand-name medications even with insurance. Visit our for details.

What happens during the GLP-1 consultation?

Your provider will review your health history, current medications, weight loss goals, and any relevant lab work. They will explain how GLP-1 medications work, discuss potential side effects, and help you choose the right medication and starting dose. The entire visit is virtual and typically takes 15-20 minutes.

Start your path Today

Every transformation starts with a single step. Talk to a licensed FormBlends provider about whether this approach is right for you) consultations are free and confidential.

---

Sources & References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
2. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
3. Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
4. Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
5. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563
6. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. Doi:10.1056/NEJMoa2206038
7. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2 (Garvey et al., Lancet, 2023)). Lancet. 2023;402(10402):613-626. Doi:10.1016/S0140-6736(23)01200-X
8. Wadden TA, Chao AM, Engel S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3 (Wadden et al., Nat Med, 2023)). Nat Med. 2023. Doi:10.1038/s41591-023-02597-w
9. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4 (Aronne et al., JAMA, 2024)). JAMA. 2024;331(1):38-48. Doi:10.1001/jama.2023.24945
10. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391:1193-1205. Doi:10.1056/NEJMoa2404881
11. Stierman B, Afful J, Carroll MD, et al. National Health and Nutrition Examination Survey 2017-March 2020 Prepandemic Data Files. NCHS Data Brief. No. 492. CDC/NCHS. 2023.
12. Sumithran P, Prendergast LA, Delbridge E, et al. Long-Term Persistence of Hormonal Adaptations to Weight Loss. N Engl J Med. 2011;365(17):1597-1604. Doi:10.1056/NEJMoa1105816

Nothing in this article should be construed as medical advice. The information provided is educational only. Always consult with your healthcare provider before beginning, modifying, or discontinuing any medication or treatment. FormBlends connects patients with licensed providers for individualized care.

Last updated: 2026-03-24